Antiretroviral Switch From Didanosine to Tenofovir in HIV/HCV Co-infected Patients
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the impact of changing didanosine in an
effective anti-HIV regimen to tenofovir on virologic suppression. We hypothesize that, in
patients with maximal virologic suppression on a double class regimen (including two NRTIs
and an NNRTI or a PI, boosted with RTV or not), a single drug substitution of didanosine for
tenofovir will represent a viable strategy without any negative impact on the virologic
efficacy of the regimen.